Home
>
US Stocks
>
Seres Therapeutics Inc
Seres Therapeutics Inc
MCRB

Seres Therapeutics Inc (MCRB)

$6.223.15%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
6.04
Today Low/High
6 / 6.22
52 Week Low/High
$6.15 / $38.5
P/E ratio
-4.429
Market Cap
$586.08M

Company Details

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
Organisation
Seres Therapeutics Inc
Headquaters
Cambridge, Massachusetts, US
Employees
155
Industry
Health Technology
CEO
Eric Shaff

Discover more

Frequently Asked Questions

What is Seres Therapeutics Inc (MCRB) share price today?

Can Indians buy Seres Therapeutics Inc (MCRB) shares?

How can I buy Seres Therapeutics Inc (MCRB) shares from India?

Can Fractional shares of Seres Therapeutics Inc (MCRB) be purchased?

What are the documents required to start investing in Seres Therapeutics Inc (MCRB) stocks?

We are a SEBI registered investement advisor